JP2008517921A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517921A5 JP2008517921A5 JP2007538049A JP2007538049A JP2008517921A5 JP 2008517921 A5 JP2008517921 A5 JP 2008517921A5 JP 2007538049 A JP2007538049 A JP 2007538049A JP 2007538049 A JP2007538049 A JP 2007538049A JP 2008517921 A5 JP2008517921 A5 JP 2008517921A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- metformin
- administered
- laf237
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 33
- 238000000034 method Methods 0.000 claims 20
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 19
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 18
- 229960003105 metformin Drugs 0.000 claims 17
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 17
- 235000012054 meals Nutrition 0.000 claims 15
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 14
- 229960005095 pioglitazone Drugs 0.000 claims 9
- 229960004586 rosiglitazone Drugs 0.000 claims 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 7
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 5
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 5
- 239000003472 antidiabetic agent Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960003271 rosiglitazone maleate Drugs 0.000 claims 4
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 claims 4
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 229940125708 antidiabetic agent Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 claims 2
- -1 3-hydroxy-1-adamantyl Chemical group 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 102000023984 PPAR alpha Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- UIKDPMGTFQHKLC-UHFFFAOYSA-N 3-(aminomethyl)-2-(2-methylpropyl)-1-oxo-4-phenylisoquinoline-6-carboxamide Chemical compound C12=CC(C(N)=O)=CC=C2C(=O)N(CC(C)C)C(CN)=C1C1=CC=CC=C1 UIKDPMGTFQHKLC-UHFFFAOYSA-N 0.000 claims 1
- VNACOBVZDCLAEV-GXKRWWSZSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride Chemical compound Cl.Cl.N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VNACOBVZDCLAEV-GXKRWWSZSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 108090000212 dipeptidyl peptidase II Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000004140 ketosis Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62189104P | 2004-10-25 | 2004-10-25 | |
| PCT/US2005/037819 WO2006047248A1 (en) | 2004-10-25 | 2005-10-21 | Combination of dpp-iv inhibitor, ppar antidiabetic and metformin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517921A JP2008517921A (ja) | 2008-05-29 |
| JP2008517921A5 true JP2008517921A5 (https=) | 2008-11-27 |
Family
ID=35717718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538049A Pending JP2008517921A (ja) | 2004-10-25 | 2005-10-21 | Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20090253752A1 (https=) |
| EP (1) | EP1807066A1 (https=) |
| JP (1) | JP2008517921A (https=) |
| KR (1) | KR20070068407A (https=) |
| CN (1) | CN101035522B (https=) |
| AU (2) | AU2005299808B2 (https=) |
| BR (1) | BRPI0518409A2 (https=) |
| CA (1) | CA2581298A1 (https=) |
| MX (1) | MX2007004934A (https=) |
| RU (1) | RU2007119320A (https=) |
| WO (1) | WO2006047248A1 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| GT200600218A (es) * | 2005-06-10 | 2007-03-28 | Formulación y proceso de compresión directa | |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PL1931350T5 (pl) * | 2005-09-14 | 2021-11-15 | Takeda Pharmaceutical Company Limited | Podanie inhibitorów dipeptydylo-peptydazy |
| AU2011202574B2 (en) * | 2005-09-20 | 2012-02-02 | Emisphere Technologies, Inc. | Use of a DPP-IV inhibitor to reduce hypoglycemic events |
| CA2622579C (en) * | 2005-09-20 | 2013-12-31 | Novartis Ag | Use of a dpp-iv inhibitor to reduce hypoglycemic events |
| BRPI0616694B8 (pt) * | 2005-09-29 | 2021-05-25 | Novartis Ag | processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis |
| CN101365432B (zh) * | 2005-12-16 | 2011-06-22 | 默沙东公司 | 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物 |
| US20090054512A1 (en) * | 2006-01-06 | 2009-02-26 | Foley James E | Use of organic compounds |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| AU2007318059A1 (en) * | 2006-11-01 | 2008-05-15 | Novartis Ag | Use of Dipeptidyl peptidase IV inhibitors for preventing, delaying or reducing the occurance of edema |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE488227T1 (de) | 2007-02-01 | 2010-12-15 | Takeda Pharmaceutical | Feste zubereitung mit alogliptin und pioglitazon |
| CA2681092A1 (en) * | 2007-03-15 | 2008-09-18 | Nectid, Inc. | Anti-diabetic combinations comprising a slow release biguanide composition and an immediate release dipeptidyl peptidase iv inhibitor composition |
| JP5667440B2 (ja) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体 |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| US20100330177A1 (en) * | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| US8551524B2 (en) | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| CA2744817C (en) | 2008-11-26 | 2020-07-07 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| GB2465796A (en) * | 2008-12-01 | 2010-06-02 | Bee Kang Tan | Metformin for the therapeutic use of conditions with raised serum amyloid A levels |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| WO2010074271A1 (ja) * | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2395988A2 (en) * | 2009-02-13 | 2011-12-21 | Boehringer Ingelheim International GmbH | Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| BRPI1008560B1 (pt) | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| US8377947B2 (en) * | 2009-03-16 | 2013-02-19 | Chien-Hung Chen | Treating alzheimer's disease and osteoporosis and reducing aging |
| CA2771352A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| WO2011037793A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Substituted aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| WO2011049773A1 (en) * | 2009-10-23 | 2011-04-28 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone |
| EP3315124B1 (en) * | 2009-11-13 | 2021-01-06 | Astrazeneca AB | Bilayer tablet formulations |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| WO2011080276A1 (en) | 2009-12-29 | 2011-07-07 | Genfit | Pharmaceutical combinations comprising a dpp-4 inhibitor and a 1,3-diphenylprop-2-en-1-one derivative |
| EP2356985A1 (en) | 2010-02-10 | 2011-08-17 | LEK Pharmaceuticals d.d. | Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| JP5688745B2 (ja) | 2010-03-10 | 2015-03-25 | プロビオドルグ エージー | グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| EA201201509A1 (ru) * | 2010-05-05 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фармацевтические составы, содержащие пиоглитазон и линаглиптин |
| EP2575821B1 (en) | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| TR201010683A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
| WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
| AR085689A1 (es) | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| CA2852957C (en) | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| CN104023727B (zh) | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| CN106706768B (zh) * | 2015-11-17 | 2021-05-11 | 重庆医药工业研究院有限责任公司 | 一种分离测定恩格列净及其有关物质的方法 |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP3958857A1 (en) | 2019-09-17 | 2022-03-02 | Novartis AG | Combination therapy with vildagliptin and metformin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| PT1741446E (pt) * | 2000-01-21 | 2008-05-09 | Novartis Pharma Ag | Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos |
| GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| US6573287B2 (en) * | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
-
2005
- 2005-10-21 US US11/577,941 patent/US20090253752A1/en not_active Abandoned
- 2005-10-21 BR BRPI0518409-6A patent/BRPI0518409A2/pt not_active IP Right Cessation
- 2005-10-21 RU RU2007119320/15A patent/RU2007119320A/ru unknown
- 2005-10-21 AU AU2005299808A patent/AU2005299808B2/en not_active Ceased
- 2005-10-21 CN CN2005800343814A patent/CN101035522B/zh not_active Expired - Fee Related
- 2005-10-21 JP JP2007538049A patent/JP2008517921A/ja active Pending
- 2005-10-21 CA CA002581298A patent/CA2581298A1/en not_active Abandoned
- 2005-10-21 WO PCT/US2005/037819 patent/WO2006047248A1/en not_active Ceased
- 2005-10-21 EP EP05816082A patent/EP1807066A1/en not_active Withdrawn
- 2005-10-21 MX MX2007004934A patent/MX2007004934A/es unknown
- 2005-10-21 KR KR1020077009270A patent/KR20070068407A/ko not_active Ceased
-
2009
- 2009-10-01 AU AU2009222515A patent/AU2009222515A1/en not_active Abandoned
-
2011
- 2011-08-15 US US13/209,890 patent/US20110301172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517921A5 (https=) | ||
| RU2007119320A (ru) | Комбинация ингибитора dpp-iv, антидиабетического агента ppar и метформина | |
| AU2002251067B2 (en) | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative | |
| KR101345316B1 (ko) | 당뇨병 치료용 디펩티딜 펩티다아제 억제제 | |
| JP2007511487A5 (https=) | ||
| US20130123354A1 (en) | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders | |
| AU2006222060B2 (en) | Roflumilast for the treatment of diabetes mellitus | |
| US20090054450A1 (en) | Compositions and methods of use for treating or preventing lipid related disorders | |
| CN101616673A (zh) | 2-[6-(3-氨基-哌啶-1-基)-3-甲基-2,4-二氧代-3,4-二氢-2h-嘧啶-1-基甲基]-4-氟-苄腈的用途 | |
| CN1443068A (zh) | 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物 | |
| JP2008007519A5 (https=) | ||
| TW201036975A (en) | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy | |
| KR20080040643A (ko) | 의약의 병용 및 그 용도 | |
| AU2007293885A1 (en) | Combination treatment for diabetes mellitus | |
| TWI842924B (zh) | Gpr119致效劑及dpp-4抑制劑的藥物組合及藥物套組 | |
| WO2012027331A1 (en) | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders | |
| US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
| CN103142600A (zh) | 二肽基肽酶抑制剂的每周给药 | |
| WO2001082875A2 (en) | A core formulation | |
| EP1278513B1 (en) | A core formulation | |
| ES2444265T3 (es) | Composiciones farmacéuticas para el tratamiento de la diabetes mellitus | |
| JPWO2020194052A5 (https=) | ||
| RU2818562C2 (ru) | Комбинированная терапия агонистами gpr119 и ингибиторами dpp-4 | |
| JP2004536842A (ja) | トログリタゾンおよびビグアナイドを含むコア製剤 | |
| CN1883476A (zh) | 治疗糖尿病的口服复方药物组合物 |